Review Article

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Qing Li1, Ming Xiang1
1 Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China
Correspondence to: Ming Xiang: xiangming@tjmu.edu.cn,
DOI: 10.1038/s41401-021-00776-4
Received: 9 June 2021
Accepted: 7 September 2021
Advance online: 24 September 2021

Abstract

A number of emerging studies in field of immune metabolism have indicated that cellular metabolic reprograming serves as a major administrator in maintaining the viability and functions of both tumor cells and immune cells. As one of the most important immunosuppressive cells in tumor stroma, myeloid-derived suppressor cells (MDSCs) dynamically orchestrate their metabolic pathways in response to the complicated tumor microenvironment (TME), a process that consequently limits the therapeutic effectiveness of anti-cancer treatment modalities. In this context, the metabolic vulnerabilities of MDSCs could be exploited as a novel immune metabolic checkpoint upon which to intervene for promoting the efficacy of immunotherapy. Here, we have discussed about recent studies highlighting the important roles of the metabolic reprograming and the core molecular pathways involved in tumor-infiltrating MDSCs. In addition, we have also summarized the state-of-the-art strategies that are currently being employed to target MDSC metabolism and improve the efficacy of antineoplastic immunotherapy.
Keywords: myeloid-derived suppressor cells; tumor microenvironment; metabolic reprograming; cancer immunotherapy; metabolic intervention

Article Options

Download Citation

Cited times in Scopus